{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T11:52:42Z","timestamp":1780919562020,"version":"3.54.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Minufiya University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Hepatitis C virus (HCV) is the predominant viral cause of hepatocellular carcinoma (HCC). Early detection and use of reliable biological markers can improve survival for HCC patients. MiR-485-5p was identified as a tumor-suppressing microribonucleic acid (miRNA) in some human cancers and was recently found to be downregulated in HCC tissues, signifying its utility as a promising biomarker. We aimed to investigate the potential role of circulating miR-485-5p as a novel diagnostic and prognostic biomarker for HCV-related HCC. This case\u2013control study included 50 patients with HCC associated with HCV, 50 patients with HCV-related liver cirrhosis, and 50 healthy controls. History gathering, physical examination, laboratory, and imaging assessments were performed. A quantitative real-time polymerase chain reaction was used to measure miR-485-5p levels. Serum miR-485-5p values demonstrated a stepwise decline pattern from the control group to cirrhotic patients, with the HCC group exhibiting the lowest levels (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). HCC patients with early BCLC stages had significantly lower miR-485-5p levels than those with late stages (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.004). The miR-485-5p displayed a better performance in predicting HCV-related HCC with a greater area under the ROC curve (AUC) than alpha-fetoprotein (AFP) (AUC and sensitivity 0.921 and 92.0 versus 0.704 and 64.0, respectively) (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). Also, its performance in predicting HCC prognosis surpassed that of AFP (AUC and sensitivity 0.872 and 85.19 versus 0.695 and 62.96, respectively) (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). Circulating miR-485-5p is a promising, accurate, and noninvasive biomarker for the early detection and prediction of prognosis in patients with HCV-linked HCC.\n                  <\/jats:p>","DOI":"10.1007\/s10238-025-01625-y","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T02:51:51Z","timestamp":1744253511000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Circulating miR-485-5p as a potential diagnostic and prognostic biomarker for HCV-related hepatocellular carcinoma"],"prefix":"10.1007","volume":"25","author":[{"given":"Gamalat A.","family":"Elgedawy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8786-0190","authenticated-orcid":false,"given":"Naglaa S.","family":"Elabd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asmaa M.","family":"Elbrolosy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzan M.","family":"El-Morshedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayman","family":"El-Gamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1808-7928","authenticated-orcid":false,"given":"Mai","family":"Abozeid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mervat","family":"Abdelkreem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sama S.","family":"Eleowa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwa L.","family":"Helal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,10]]},"reference":[{"key":"1625_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"1625_CR2","first-page":"7","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7\u201333.","journal-title":"CA Cancer J Clin"},{"key":"1625_CR3","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/ijc.32723","volume":"147","author":"JL Petrick","year":"2020","unstructured":"Petrick JL, Florio AA, Znaor A, Ruggieri D, Laversanne M, Alvarez CS, et al. International trends in hepatocellular carcinoma incidence, 1978\u20132012. Int J Cancer. 2020;147:317\u201330.","journal-title":"Int J Cancer"},{"key":"1625_CR4","doi-asserted-by":"crossref","first-page":"559","DOI":"10.3390\/v15020559","volume":"15","author":"TH Yang","year":"2023","unstructured":"Yang TH, Chan C, Yang PJ, Huang YH, Lee MH. Genetic susceptibility to hepatocellular carcinoma in patients with chronic hepatitis virus infection. Viruses. 2023;15:559.","journal-title":"Viruses"},{"key":"1625_CR5","doi-asserted-by":"crossref","first-page":"101423","DOI":"10.1016\/j.coviro.2024.101423","volume":"67","author":"F Fiehn","year":"2024","unstructured":"Fiehn F, Beisel C, Binder M. Hepatitis C virus and hepatocellular carcinoma: carcinogenesis in the era of direct-acting antivirals. Curr Opin Virol. 2024;67:101423.","journal-title":"Curr Opin Virol"},{"key":"1625_CR6","first-page":"1","volume":"21","author":"F Feng","year":"2024","unstructured":"Feng F, Zhao Y. Hepatocellular carcinoma: prevention, diagnosis, and treatment. Med Princ Pract. 2024;21:1\u201310.","journal-title":"Med Princ Pract"},{"key":"1625_CR7","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s12943-024-02101-z","volume":"23","author":"YT Chan","year":"2024","unstructured":"Chan YT, Zhang C, Wu J, Lu P, Xu L, Yuan H, et al. Biomarkers for diagnosis and therapeutic options in hepatocellular carcinoma. Mol Cancer. 2024;23:189.","journal-title":"Mol Cancer"},{"key":"1625_CR8","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3748\/wjg.v28.i2.216","volume":"28","author":"H Hanif","year":"2022","unstructured":"Hanif H, Ali MJ, Susheela AT, Khan IW, Luna-Cuadros MA, Khan MM, et al. Update on the applications and limitations of alpha-fetoprotein for hepatocellular carcinoma. World J Gastroenterol. 2022;28:216\u201329.","journal-title":"World J Gastroenterol"},{"key":"1625_CR9","doi-asserted-by":"crossref","first-page":"337","DOI":"10.5114\/ceh.2021.111060","volume":"7","author":"HS Sabry","year":"2021","unstructured":"Sabry HS, Tayel SI, Enar ME, Elabd NS. Differential expression of long noncoding RNA in hepatocellular carcinoma on top of chronic HCV and HBV infections. Clin Exp Hepatol. 2021;7:337\u201350.","journal-title":"Clin Exp Hepatol"},{"key":"1625_CR10","doi-asserted-by":"crossref","first-page":"100808","DOI":"10.1016\/j.mgene.2020.100808","volume":"26","author":"SE Soliman","year":"2020","unstructured":"Soliman SE, ElTorgoman AMA, Assar MFA, Elabd NS, Gohar SF, Girgis RE. Biochemical and molecular study of long non-coding RNAs (HOTTIP, ZEB-AS1 and MEG-3) in hepatocellular carcinoma. Meta Gene. 2020;26:100808.","journal-title":"Meta Gene"},{"key":"1625_CR11","doi-asserted-by":"crossref","first-page":"7268","DOI":"10.3390\/ijms24087268","volume":"24","author":"L Pekarek","year":"2023","unstructured":"Pekarek L, Torres-Carranza D, Fraile-Martinez O, Garc\u00eda-Montero C, Pekarek T, Saez MA, et al. An overview of the role of MicroRNAs on carcinogenesis: a focus on cell cycle, angiogenesis and metastasis. Int J Mol Sci. 2023;24:7268.","journal-title":"Int J Mol Sci"},{"key":"1625_CR12","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.3748\/wjg.v28.i22.2417","volume":"28","author":"E Badami","year":"2022","unstructured":"Badami E, Bus\u00e0 R, Douradinha B, Russelli G, Miceli V, Gallo A, et al. Hepatocellular carcinoma, hepatitis C virus infection and miRNA involvement: perspectives for new therapeutic approaches. World J Gastroenterol. 2022;28:2417\u201328.","journal-title":"World J Gastroenterol"},{"key":"1625_CR13","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2147\/HMER.S292251","volume":"13","author":"NS Elabd","year":"2021","unstructured":"Elabd NS, Tayel SI, Elhamouly MS, Hassanein SA, Kamaleldeen SM, Ahmed FE, et al. Evaluation of MicroRNA-122 as a biomarker for chronic hepatitis C infection and as a predictor for treatment response to direct-acting antivirals. Hepat Med. 2021;13:9\u201323.","journal-title":"Hepat Med"},{"key":"1625_CR14","doi-asserted-by":"crossref","first-page":"9393","DOI":"10.3390\/ijms25179393","volume":"25","author":"K Mahboobnia","year":"2024","unstructured":"Mahboobnia K, Beveridge DJ, Yeoh GC, Kabir TD, Leedman PJ. MicroRNAs in hepatocellular carcinoma pathogenesis: insights into mechanisms and therapeutic opportunities. Int J Mol Sci. 2024;25:9393.","journal-title":"Int J Mol Sci"},{"key":"1625_CR15","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.biopha.2017.03.064","volume":"90","author":"J Wu","year":"2017","unstructured":"Wu J, Li J, Ren J, Zhang D. MicroRNA-485-5p represses melanoma cell invasion and proliferation by suppressing Frizzled7. Biomed Pharmacother. 2017;90:303\u201310.","journal-title":"Biomed Pharmacother"},{"key":"1625_CR16","first-page":"7197","volume":"22","author":"FR Wang","year":"2018","unstructured":"Wang FR, Xu SH, Wang BM, Wang F. MiR-485-5p inhibits metastasis and proliferation of osteosarcoma by targeting CX3CL1. Eur Rev Med Pharmacol Sci. 2018;22:7197\u2013204.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"1625_CR17","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.bbrc.2018.04.129","volume":"501","author":"M Wang","year":"2018","unstructured":"Wang M, Cai WR, Meng R, Chi JR, Li YR, Chen AX, et al. miR-485-5p suppresses breast cancer progression and chemosensitivity by targeting survivin. Biochem Biophys Res Commun. 2018;501:48\u201354.","journal-title":"Biochem Biophys Res Commun"},{"key":"1625_CR18","first-page":"2507","volume":"8","author":"R Wang","year":"2018","unstructured":"Wang R, Zuo X, Wang K, Han Q, Zuo J, Ni H, et al. MicroRNA-485-5p attenuates cell proliferation in glioma by directly targeting paired box 3. Am J Cancer Res. 2018;8:2507\u201317.","journal-title":"Am J Cancer Res"},{"key":"1625_CR19","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.7150\/jca.24918","volume":"9","author":"XX Hu","year":"2018","unstructured":"Hu XX, Xu XN, He BS, Sun HL, Xu T, Liu XX, et al. microRNA-485-5p functions as a tumor suppressor in colorectal cancer cells by targeting CD147. J Cancer. 2018;9:2603\u201311.","journal-title":"J Cancer"},{"key":"1625_CR20","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1111\/1759-7714.14475","volume":"13","author":"Y Liu","year":"2022","unstructured":"Liu Y, Zhang Y, Li Q, Xu R, Huang N. MiR-200c-3p and miR-485-5p overexpression elevates cisplatin sensitivity and suppresses the malignant phenotypes of non-small cell lung cancer cells through targeting RRM2. Thorac Cancer. 2022;13:1974\u201385.","journal-title":"Thorac Cancer"},{"key":"1625_CR21","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.biopha.2015.04.008","volume":"72","author":"X Sun","year":"2015","unstructured":"Sun X, Liu Y, Li M, Wang M, Wang Y. Involvement of miR-485-5p in hepatocellular carcinoma progression targeting EMMPRIN. Biomed Pharmacother. 2015;72:58\u201365.","journal-title":"Biomed Pharmacother"},{"key":"1625_CR22","first-page":"12292","volume":"8","author":"GX Guo","year":"2015","unstructured":"Guo GX, Li QY, Ma WL, Shi ZH, Ren XQ. MicroRNA-485-5p suppresses cell proliferation and invasion in hepatocellular carcinoma by targeting stanniocalcin 2. Int J Clin Exp Pathol. 2015;8:12292\u20139.","journal-title":"Int J Clin Exp Pathol"},{"key":"1625_CR23","doi-asserted-by":"crossref","first-page":"109466","DOI":"10.1016\/j.cellsig.2019.109466","volume":"66","author":"J Gao","year":"2020","unstructured":"Gao J, Dai C, Yu X, Yin XB, Zhou F. microRNA-485-5p inhibits the progression of hepatocellular carcinoma through blocking the WBP2\/Wnt signaling pathway. Cell Signal. 2020;66:109466.","journal-title":"Cell Signal"},{"key":"1625_CR24","doi-asserted-by":"crossref","first-page":"109213","DOI":"10.1016\/j.biopha.2019.109213","volume":"118","author":"J Tu","year":"2019","unstructured":"Tu J, Zhao Z, Xu M, Chen M, Weng Q, Ji J. LINC00460 promotes hepatocellular carcinoma development through sponging miR-485-5p to up-regulate PAK1. Biomed Pharmacother. 2019;118:109213.","journal-title":"Biomed Pharmacother"},{"key":"1625_CR25","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1007\/s00210-020-01889-z","volume":"393","author":"W Zhang","year":"2020","unstructured":"Zhang W, Han L, Xing P, Liu B, Sun Z, Zhou W, et al. LncRNA RHPN1-AS1 accelerates proliferation, migration, and invasion via regulating miR-485-5p\/BSG axis in hepatocellular carcinoma. Naunyn Schmiedebergs Arch Pharmacol. 2020;393:2543\u201351.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"1625_CR26","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41417-021-00312-w","volume":"29","author":"L Yang","year":"2022","unstructured":"Yang L, Deng WL, Zhao BG, Xu Y, Wang XW, Fang Y, et al. FOXO3-induced lncRNA LOC554202 contributes to hepatocellular carcinoma progression via the miR-485-5p\/BSG axis. Cancer Gene Ther. 2022;29:326\u201340.","journal-title":"Cancer Gene Ther"},{"key":"1625_CR27","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2217\/bmm-2019-0534","volume":"14","author":"Y Pan","year":"2020","unstructured":"Pan Y, Qin J, Sun H, Xu T, Wang S, He B. MiR-485-5p as a potential biomarker and tumor suppressor in human colorectal cancer. Biomark Med. 2020;14:239\u201348.","journal-title":"Biomark Med"},{"key":"1625_CR28","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s12894-022-01143-z","volume":"22","author":"W He","year":"2022","unstructured":"He W, Zhang F, Jiang F, Liu H, Wang G. Correlations between serum levels of microRNA-148a-3p and microRNA-485-5p and the progression and recurrence of prostate cancer. BMC Urol. 2022;22:195.","journal-title":"BMC Urol"},{"key":"1625_CR29","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","volume":"78","author":"JK Heimbach","year":"2023","unstructured":"Heimbach JK, Dawson LA, Jou JH, Kulik LM, Agopian VG, Marrero JA, et al. AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023;78:1922\u201365.","journal-title":"Hepatology"},{"key":"1625_CR30","doi-asserted-by":"crossref","first-page":"100535","DOI":"10.1016\/j.aohep.2021.100535","volume":"27","author":"A Ruf","year":"2022","unstructured":"Ruf A, Dirchwolf M, Freeman RB. From child-pugh to MELD score and beyond: taking a walk down memory lane. Ann Hepatol. 2022;27:100535.","journal-title":"Ann Hepatol"},{"key":"1625_CR31","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","volume":"76","author":"M Reig","year":"2022","unstructured":"Reig M, Forner A, Rimola J, Ferrer-F\u00e0brega J, Burrel M, Garcia-Criado \u00c1, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76:681\u201393.","journal-title":"J Hepatol"},{"key":"1625_CR32","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.4251\/wjgo.v13.i12.1919","volume":"13","author":"R Ezzat","year":"2021","unstructured":"Ezzat R, Eltabbakh M, El Kassas M. Unique situation of hepatocellular carcinoma in Egypt: a review of epidemiology and control measures. World J Gastrointest Oncol. 2021;13:1919\u201338.","journal-title":"World J Gastrointest Oncol"},{"issue":"Suppl 2","key":"1625_CR33","doi-asserted-by":"crossref","first-page":"S361","DOI":"10.21037\/jgo.2020.02.08","volume":"12","author":"H Samant","year":"2021","unstructured":"Samant H, Amiri HS, Zibari GB. Addressing the worldwide hepatocellular carcinoma: epidemiology, prevention and management. J Gastrointest Oncol. 2021;12(Suppl 2):S361\u201373.","journal-title":"J Gastrointest Oncol"},{"key":"1625_CR34","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.jfma.2024.01.015","volume":"123","author":"S Maekawa","year":"2024","unstructured":"Maekawa S, Takano S, Enomoto N. Risk of hepatocellular carcinoma after viral clearance achieved by DAA treatment. J Formos Med Assoc. 2024;123:1124\u201330.","journal-title":"J Formos Med Assoc"},{"key":"1625_CR35","doi-asserted-by":"crossref","first-page":"3817724","DOI":"10.1155\/2022\/3817724","volume":"2022","author":"A Jose","year":"2022","unstructured":"Jose A, Bavetta MG, Martinelli E, Bronte F, Giunta EF, Manu KA. Hepatocellular carcinoma: current therapeutic algorithm for localized and advanced disease. J Oncol. 2022;2022:3817724.","journal-title":"J Oncol"},{"key":"1625_CR36","doi-asserted-by":"crossref","first-page":"9018","DOI":"10.3390\/ijms24109018","volume":"24","author":"D Gabbia","year":"2023","unstructured":"Gabbia D, De Martin S. Toward a new era in the management of hepatocellular carcinoma: novel perspectives on therapeutic options and biomarkers. Int J Mol Sci. 2023;24:9018.","journal-title":"Int J Mol Sci"},{"key":"1625_CR37","first-page":"4842","volume":"23","author":"W L-Wang","year":"2019","unstructured":"L-Wang W, Wang HR, Ji WG, Guo SL, Li HX, Xu XY. MiRNA-485\u20135p suppresses the proliferation of acute myeloid leukemia via targeting SALL4. Eur Rev Med Pharmacol Sci. 2019;23:4842\u20139.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"1625_CR38","doi-asserted-by":"crossref","first-page":"e25114","DOI":"10.1371\/journal.pone.0025114","volume":"6","author":"FF Costa","year":"2011","unstructured":"Costa FF, Bischof JM, Vanin EF, Lulla RR, Wang M, Sredni ST, et al. Identification of microRNAs as potential prognostic markers in ependymoma. PLoS ONE. 2011;6:e25114.","journal-title":"PLoS ONE"},{"key":"1625_CR39","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/j.1365-2559.2010.03686.x","volume":"57","author":"TH Kim","year":"2010","unstructured":"Kim TH, Kim YK, Kwon Y, Heo JH, Kang H, Kim G, et al. Deregulation of miR-519a, 153, and 485\u20135p and its clinicopathological relevance in ovarian epithelial tumours. Histopathology. 2010;57:734\u201343.","journal-title":"Histopathology"},{"key":"1625_CR40","doi-asserted-by":"crossref","first-page":"e2159","DOI":"10.1038\/cddis.2016.27","volume":"7","author":"C Lou","year":"2016","unstructured":"Lou C, Xiao M, Cheng S, Lu X, Jia S, Ren Y, et al. MiR-485-3p and miR-485-5p suppress breast cancer cell metastasis by inhibiting PGC-1\u03b1 expression. Cell Death Dis. 2016;7:e2159.","journal-title":"Cell Death Dis"},{"key":"1625_CR41","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1097\/CM9.0000000000000917","volume":"133","author":"QL Jiang","year":"2020","unstructured":"Jiang QL, Feng SJ, Yang ZY, Xu Q, Wang SZ. CircHECTD1 up-regulates mucin 1 expression to accelerate hepatocellular carcinoma development by targeting microRNA-485-5p via a competing endogenous RNA mechanism. Chin Med J (Engl). 2020;133:1774\u201385.","journal-title":"Chin Med J (Engl)"},{"key":"1625_CR42","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/s41419-018-0937-7","volume":"9","author":"Y Wang","year":"2018","unstructured":"Wang Y, Sun L, Wang L, Liu Z, Li Q, Yao B, et al. Long non-coding RNA DSCR8 acts as a molecular sponge for miR-485-5p to activate Wnt\/\u03b2-catenin signal pathway in hepatocellular carcinoma. Cell Death Dis. 2018;9:851.","journal-title":"Cell Death Dis"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01625-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-01625-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01625-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:45:24Z","timestamp":1764917124000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-01625-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,10]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1625"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-01625-y","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,10]]},"assertion":[{"value":"13 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Following the research questions and the research objectives were elaborated, all participants were informed about the nature of the study and asked to provide written informed consent before beginning. The National Liver Institute at Menoufia University's local ethics committee approved the study (IRB: NLI 00003413), and it was conducted in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"110"}}